MSHLRituximab (MabThera) Solution For Subcutaneous Injection 1,400 mg/11.7 mL
1) Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), for the treatment of CD20+ diffuse large B-cell non-Hodgkin lymphoma.
2) Rituximab (subcutaneous) in combination with cyclophosphamide, vincristine, prednisone (CVP), for the treatment of previously untreated patients with stage III–IV follicular lymphoma.
3) Rituximab (subcutaneous) for maintenance treatment of patients with follicular lymphoma who have responded to induction therapy.